124 related articles for article (PubMed ID: 23046448)
1. Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants.
Rodríguez M; Pérez L; Gavilondo JV; Garrido G; Bequet-Romero M; Hernández I; Huerta V; Cabrera G; Pérez M; Ramos O; Leyva R; León M; Ramos PL; Triguero A; Hernández A; Sánchez B; Ayala M; Soto J; González E; Mendoza O; Tiel K; Pujol M
Plant Biotechnol J; 2013 Jan; 11(1):53-65. PubMed ID: 23046448
[TBL] [Abstract][Full Text] [Related]
2. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor.
Rodríguez M; Ramírez NI; Ayala M; Freyre F; Pérez L; Triguero A; Mateo C; Selman-Housein G; Gavilondo JV; Pujol M
Biotechnol Bioeng; 2005 Jan; 89(2):188-94. PubMed ID: 15584026
[TBL] [Abstract][Full Text] [Related]
3. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
Ludwig DL; Witte L; Hicklin DJ; Prewett M; Bassi R; Burtrum D; Pereira DS; Jimenez X; Fox F; Saxena B; Zhou Q; Ma Y; Kang X; Patel D; Barry M; Kussie P; Zhu Z; Russell DA; Petersen WL; Jury TP; Gaitan-Gaitan F; Moran DL; Delannay X; Storrs BS; Tou J; Zupec ME; Gustafson KS; McIntyre J; Tarnowski SJ; Bohlen P
Hum Antibodies; 2004; 13(3):81-90. PubMed ID: 15598988
[TBL] [Abstract][Full Text] [Related]
4. Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells.
Grohs BM; Niu Y; Veldhuis LJ; Trabelsi S; Garabagi F; Hassell JA; McLean MD; Hall JC
J Agric Food Chem; 2010 Sep; 58(18):10056-63. PubMed ID: 20799692
[TBL] [Abstract][Full Text] [Related]
5. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of an anti-(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen.
Ramírez N; Rodríguez M; Ayala M; Cremata J; Pérez M; Martínez A; Linares M; Hevia Y; Páez R; Valdés R; Gavilondo JV; Selman-Housein G
Biotechnol Appl Biochem; 2003 Dec; 38(Pt 3):223-30. PubMed ID: 12797866
[TBL] [Abstract][Full Text] [Related]
7. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
Berger C; Krengel U; Stang E; Moreno E; Madshus IH
J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
[TBL] [Abstract][Full Text] [Related]
8. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
10. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
11. Expression of functional epidermal growth factor receptors in a human hematopoietic cell line.
Oval J; Hershberg R; Gansbacher B; Gilboa E; Schlessinger J; Taetle R
Cancer Res; 1991 Jan; 51(1):150-6. PubMed ID: 1703031
[TBL] [Abstract][Full Text] [Related]
12. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
Hur BU; Yoon JB; Liu LK; Cha SH
Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
Chang C; Takayanagi A; Yoshida T; Shimizu N
Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
18. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.
Barta P; Laznickova A; Laznicek M; Vera DR; Beran M
J Labelled Comp Radiopharm; 2013 May; 56(5):280-8. PubMed ID: 24285372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
